AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16779878 — intervention group
Group type: COMPARATOR
Intervention: No ointment
Number of subjects: 778
Study 16779878 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin ointment
Number of subjects: 778
Study 16779878 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin ointment
Number of subjects: 778
Study 10968910 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with aspirin and heparin
Number of subjects: 0
Study 8859914 — intervention group
Group type: EXPERIMENTAL
Intervention: Appointment group - given a follow-up appointment in the ED prior to discharge and written reminder
Number of subjects: 253
Study 8859914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense group - given a follow-up appointment in the ED prior to discharge, a written reminder, work excuse, child care, transportation assistance, mailed reminders, and telephone reminders
Number of subjects: 253
Study 8859914 — intervention group
Group type: COMPARATOR
Intervention: Control group - told to call the clinic for follow-up appointments
Number of subjects: 253
Study 8859914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense group - successful telephone contact
Number of subjects: 253
Study 8859914 — intervention group
Group type: EXPERIMENTAL
Intervention: Families left to make their own follow-up appointments
Number of subjects: 253
Study 8859914 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 253
Study 1463530 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 to 20 mg per day)
Number of subjects: 4228
Study 1463530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4228
Study 6733393 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 7.5 mg
Number of subjects: 60
Study 6733393 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 12.5 mg
Number of subjects: 60
Study 6733393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30742838 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) ingestion
Number of subjects: 12
Study 30742838 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) ingestion
Number of subjects: 12
Study 29576535 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric Restriction (CR)
Number of subjects: 53
Study 29576535 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 53
Study 26135372 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive underwater exercises and interferential current therapy
Number of subjects: 30
Study 26135372 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy program (Control)
Number of subjects: 30
Study 24246718 — intervention group
Group type: EXPERIMENTAL
Intervention: Active reading condition
Number of subjects: 638
Study 24246718 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive reading condition
Number of subjects: 638
Study 24246718 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (Study 2)
Number of subjects: 638
Study 24246718 — intervention group
Group type: COMPARATOR
Intervention: Control group (Study 2)
Number of subjects: 638
Study 21415232 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual health promotion messages via SMS and email (n=507)
Number of subjects: 994
Study 21415232 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=487)
Number of subjects: 994
Study 22009840 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment through the paravertebral muscle approach
Number of subjects: 62
Study 22009840 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgical procedure
Number of subjects: 62
Study 17156263 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 1062
Study 17156263 — intervention group
Group type: COMPARATOR
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 1062
Study 15830922 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic lycopene
Number of subjects: 0
Study 15830922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyc-o-Mato
Number of subjects: 0
Study 15830922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyc-o-Guard-Drink
Number of subjects: 0
Study 11976195 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet adequate in vitamin C
Number of subjects: 0
Study 11976195 — intervention group
Group type: COMPARATOR
Intervention: Diet deficient in vitamin C
Number of subjects: 0
Study 9473971 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week psychoeducational intervention (2 h/week)
Number of subjects: 78
Study 9473971 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week education intervention (1 h/week)
Number of subjects: 78
Study 9473971 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 7635995 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (up to 60 mg/day)
Number of subjects: 101
Study 7635995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 31177248 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS with AO
Number of subjects: 22
Study 31177248 — intervention group
Group type: COMPARATOR
Intervention: rTMS alone
Number of subjects: 22
Study 28371571 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 50
Study 28371571 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 50
Study 25399306 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinlongshe Granule (JLSG)
Number of subjects: 50
Study 25399306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23194834 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg)
Number of subjects: 50
Study 23194834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21530058 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1700‐3000 mg/day)
Number of subjects: 208
Study 21530058 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal pregnant women)
Number of subjects: 208
Study 19117084 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley starch syrup
Number of subjects: 15
Study 19117084 — intervention group
Group type: COMPARATOR
Intervention: Cereals (wheat, barley, rye, oats)
Number of subjects: 15
Study 19117084 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-prick tests (SPT)
Number of subjects: 15
Study 16781068 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (up to 15 sessions over three months)
Number of subjects: 1880
Study 16781068 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care alone)
Number of subjects: 1880
Study 15291866 — intervention group
Group type: COMPARATOR
Intervention: Ileal conduit diversion (group 1)
Number of subjects: 162
Study 15291866 — intervention group
Group type: COMPARATOR
Intervention: Modified S-pouch neobladder (group 2)
Number of subjects: 162
Study 15291866 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group 3)
Number of subjects: 162
Study 11532741 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B(6)
Number of subjects: 15
Study 11532741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9421774 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 h change of infusion systems
Number of subjects: 19
Study 9421774 — intervention group
Group type: EXPERIMENTAL
Intervention: 96 h change of infusion systems
Number of subjects: 19
Study 9421774 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line infusion filters
Number of subjects: 19
Study 9421774 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-bound endotoxin
Number of subjects: 19
Study 9421774 — intervention group
Group type: EXPERIMENTAL
Intervention: Free endotoxin
Number of subjects: 19
Study 8214738 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal lidocaine administration
Number of subjects: 0
Study 8214738 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep endobronchial lidocaine administration
Number of subjects: 0
Study 3307601 — intervention group
Group type: EXPERIMENTAL
Intervention: DDP (Cisplatinum) 100 mg/m2 administered on day 1
Number of subjects: 136
Study 3307601 — intervention group
Group type: COMPARATOR
Intervention: DDP-Etoposide (DDP 100 mg/m2 on day 4 and Etoposide 100 mg/m2 per os on days 1 to 5)
Number of subjects: 136
Study 3307601 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DDP and DDP-Etoposide)
Number of subjects: 136
Study 31743039 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilized leg (7 days of unilateral leg immobilization)
Number of subjects: 13
Study 31743039 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilized leg (2 days of immobilization)
Number of subjects: 13
Study 31743039 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilized leg (7 days of immobilization)
Number of subjects: 13
Study 31743039 — intervention group
Group type: COMPARATOR
Intervention: Control leg (non-immobilized leg)
Number of subjects: 13
Study 31743039 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilized leg
Number of subjects: 13
Study 29577247 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of a water-in-oil emulsion with pH 4
Number of subjects: 0
Study 29577247 — intervention group
Group type: COMPARATOR
Intervention: Topical application of a water-in-oil emulsion with pH 5.8
Number of subjects: 0
Study 29278471 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonglin Powder
Number of subjects: 100
Study 29278471 — intervention group
Group type: COMPARATOR
Intervention: Terazosin
Number of subjects: 100
Study 25158949 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching fluoride-releasing primer (Transbond™ Plus; group C)
Number of subjects: 15
Study 25158949 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acid-etching with 35% phosphoric acid and Transbond™ XT (group D)
Number of subjects: 15
Study 25158949 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching non-fluoride primer (iBond™ Gluma® Inside; group B)
Number of subjects: 15
Study 25158949 — intervention group
Group type: COMPARATOR
Intervention: Untreated control sample (group A)
Number of subjects: 15
Study 23259262 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of scalp and body acupuncture by stages (specific acupoints selected based on disease stage).
Number of subjects: 96
Study 23259262 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of scalp and body acupuncture by stages.
Number of subjects: 96
Study 23259262 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture (no scalp acupuncture, acupoints not selected by disease stage).
Number of subjects: 96
Study 20855284 — intervention group
Group type: EXPERIMENTAL
Intervention: Bufeishenqingre decoction, administered twice a day for one month.
Number of subjects: 60
Study 20855284 — intervention group
Group type: COMPARATOR
Intervention: Theophylline sustained-release capsules, 100 mg administered twice a day for one month.
Number of subjects: 60
Study 18304674 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling intervention using continuous glucose monitoring system (CGMS) feedback
Number of subjects: 52
Study 18304674 — intervention group
Group type: COMPARATOR
Intervention: Diabetes education (control group)
Number of subjects: 52
Study 16172456 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI‐007 260 mg/m² intravenously without premedication
Number of subjects: 454
Study 16172456 — intervention group
Group type: COMPARATOR
Intervention: Standard paclitaxel 175 mg/m² intravenously with premedication
Number of subjects: 454
Study 12609940 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 000 IU oral vitamin D3 (cholecalciferol) supplementation every four months
Number of subjects: 2686
Study 12609940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2686
Study 10591988 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep phase advance (SPA) - time in bed scheduled from 1700-2400 hrs
Number of subjects: 40
Study 10591988 — intervention group
Group type: COMPARATOR
Intervention: Sleep phase delay (SPD) - time in bed from 0200-0700 hrs
Number of subjects: 40
Study 8946863 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosquamous cell type
Number of subjects: 813
Study 8946863 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenocarcinoma
Number of subjects: 813
Study 8946863 — intervention group
Group type: EXPERIMENTAL
Intervention: Squamous carcinoma
Number of subjects: 813
Study 8946863 — intervention group
Group type: COMPARATOR
Intervention: All cell types
Number of subjects: 813
Study 1657078 — intervention group
Group type: EXPERIMENTAL
Intervention: CVM (carboplatin 300 mg/m2, vinblastine 6 mg/m2, methotrexate 30 mg/m2, intravenously every 4 weeks)
Number of subjects: 104
Study 1657078 — intervention group
Group type: COMPARATOR
Intervention: ACE (doxorubicin 40 mg/m2, cyclophosphamide 600 mg/m2, etoposide 100 mg/m2, intravenously day 1-3, every 3 weeks)
Number of subjects: 104
Study 1657078 — intervention group
Group type: EXPERIMENTAL
Intervention: CVM
Number of subjects: 104
Study 1657078 — intervention group
Group type: COMPARATOR
Intervention: ACE
Number of subjects: 104
Study 6816061 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplementation program
Number of subjects: 0
Study 6816061 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplementation program combined with a home education program
Number of subjects: 0
Study 30729881 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving-based intervention focused on caregiver medication management
Number of subjects: 83
Study 30729881 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 83
Study 30729881 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving-based intervention
Number of subjects: 83
Study 30510434 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg
Number of subjects: 103
Study 30510434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 26850307 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD/FM 160/4.5 μg plus as-needed BUD/FM (SMART group, n=15)
Number of subjects: 30
Study 26850307 — intervention group
Group type: COMPARATOR
Intervention: FF/VI 100/25 μg plus as-needed procaterol (FF/VI group, n=15)
Number of subjects: 30
Study 25140986 — intervention group
Group type: EXPERIMENTAL
Intervention: X3 crosslinked polyethylene (XLPE) liner
Number of subjects: 24
Study 25140986 — intervention group
Group type: COMPARATOR
Intervention: Conventional polyethylene (CPE) liner
Number of subjects: 24
Study 22429600 — intervention group
Group type: EXPERIMENTAL
Intervention: pedometer-based walking programme plus physical activity consultations
Number of subjects: 79
Study 22429600 — intervention group
Group type: COMPARATOR
Intervention: pedometer-based walking programme and minimal advice
Number of subjects: 79
Study 19842037 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple CARE for Parents (CCP)
Number of subjects: 71
Study 19842037 — intervention group
Group type: COMPARATOR
Intervention: Becoming a Parent (BAP)
Number of subjects: 71
Study 16712981 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation Therapy (VT)
Number of subjects: 30
Study 16712981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorial Reminiscence (SR)
Number of subjects: 30
Study 16712981 — intervention group
Group type: COMPARATOR
Intervention: No Treatment (Control)
Number of subjects: 30
Study 15844684 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening questionnaire
Number of subjects: 196
Study 15844684 — intervention group
Group type: COMPARATOR
Intervention: Screening interview
Number of subjects: 196
Study 12518931 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (up to 40 mg/day, with furosemide if needed)
Number of subjects: 30
Study 12518931 — intervention group
Group type: COMPARATOR
Intervention: Lacidipine (up to 8 mg/day)
Number of subjects: 30
Study 12518931 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 30
Study 10520979 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (0.25 to 4.0 mg in 2 divided doses)
Number of subjects: 438
Study 10520979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study 10520979 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (during tapering)
Number of subjects: 438
Study 10520979 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 438
Study 7741289 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis 1.0 mA for 2 h (120 mA.min)
Number of subjects: 5
Study 7741289 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis 2.0 mA for 2 h (240 mA.min)
Number of subjects: 5
Study 7741289 — intervention group
Group type: COMPARATOR
Intervention: Passive treatment 0.0 mA for 2 h (0 mA.min)
Number of subjects: 5
Study 2201625 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFA test
Number of subjects: 39
Study 2201625 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 6752708 — intervention group
Group type: EXPERIMENTAL
Intervention: J5 antiserum
Number of subjects: 212
Study 6752708 — intervention group
Group type: COMPARATOR
Intervention: Preimmune control serum
Number of subjects: 212
Study 30341695 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum tDCS (2.0 mA)
Number of subjects: 6
Study 30341695 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 6
Study 27666126 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg for 5 days
Number of subjects: 22
Study 27666126 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg plus hydrochlorothiazide 25 mg for 5 days
Number of subjects: 22
Study 27666126 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg plus torasemide 5 mg for 5 days
Number of subjects: 22
Study 27666126 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg for 4 days
Number of subjects: 22
Study 27666126 — intervention group
Group type: COMPARATOR
Intervention: Torasemide 5 mg for 4 days
Number of subjects: 22
Study 25710925 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) scan
Number of subjects: 473
Study 25710925 — intervention group
Group type: COMPARATOR
Intervention: Coronary computed tomographic angiography (CCTA)
Number of subjects: 473
Study 23589316 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (Control group, N=31)
Number of subjects: 72
Study 23589316 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of chemotherapy drugs and intraperitoneal perfusion of verapamil (Combined treatment group, N=41)
Number of subjects: 72
Study 23589316 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=31)
Number of subjects: 72
Study 23589316 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (N=41)
Number of subjects: 72
Study 20620720 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril + Amlodipine (B+A)
Number of subjects: 6946
Study 20620720 — intervention group
Group type: COMPARATOR
Intervention: Benazepril + Hydrochlorothiazide (B+H)
Number of subjects: 6946
Study 20620720 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril + Amlodipine (B+A) in very high risk diabetic patients
Number of subjects: 6946
Study 20620720 — intervention group
Group type: COMPARATOR
Intervention: Benazepril + Hydrochlorothiazide (B+H) in very high risk diabetic patients
Number of subjects: 6946
Study 20620720 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril + Amlodipine (B+A) in nondiabetic patients
Number of subjects: 6946
Study 20620720 — intervention group
Group type: COMPARATOR
Intervention: Benazepril + Hydrochlorothiazide (B+H) in nondiabetic patients
Number of subjects: 6946
Study 18391133 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (COMB)
Number of subjects: 439
Study 18391133 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 439
Study 18391133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 439
Study 18391133 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 439
Study 16640253 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat-shaded rendering condition
Number of subjects: 0
Study 16640253 — intervention group
Group type: COMPARATOR
Intervention: Radiosity rendering condition
Number of subjects: 0
Study 12781926 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual coaching on communication skills and confidence in health consultations
Number of subjects: 384
Study 12781926 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no coaching)
Number of subjects: 384
Study 10647797 — intervention group
Group type: COMPARATOR
Intervention: Peak CK-MB levels 0-1 times normal
Number of subjects: 8250
Study 10647797 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak CK-MB levels 1-2 times normal
Number of subjects: 8250
Study 10647797 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak CK-MB levels 3-5 times normal
Number of subjects: 8250
Study 10647797 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak CK-MB levels greater than 10 times normal
Number of subjects: 8250
Study 9233995 — intervention group
Group type: EXPERIMENTAL
Intervention: DCA 2000 system
Number of subjects: 1016
Study 8245520 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (1770 pfu/dose)
Number of subjects: 90
Study 8245520 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (400‐500 pfu/dose)
Number of subjects: 90
Study 8245520 — intervention group
Group type: COMPARATOR
Intervention: Group C (80‐160 pfu/dose)
Number of subjects: 90
Study 3896659 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release indomethacin (50 mg)
Number of subjects: 21
Study 3896659 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (250 mg)
Number of subjects: 21
Study 31264055 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise (n = 36)
Number of subjects: 54
Study 31264055 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL; n = 18)
Number of subjects: 54
Study 29023192 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with Methylene Blue dye (0.01%) and laser therapy (660 nm, 30 mW, 8 sec, 6 J/cm2, beam area of 0.04 mm2), three times per week for 10 sessions
Number of subjects: 12
Study 29023192 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with collagenase/chloramphenicol
Number of subjects: 12